Does Riociguat Interact with Abacavir Lamivudine And Zidovudine?
CDI records a moderate classification for Riociguat and Abacavir Lamivudine And Zidovudine. The stored summary is: Coadministration with abacavir/lamivudine may increase riociguat exposure and risk of adverse reactions; riociguat dose reduction may be needed. The mechanism involves increased riociguat exposure. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Riociguat Class
- Soluble Guanylate Cyclase Stimulator
- Abacavir Lamivudine And Zidovudine Class
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Increased riociguat exposure
What To Tell Your Doctor or Pharmacist
If you are taking Riociguat and your doctor is considering prescribing Abacavir Lamivudine And Zidovudine (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider